var data={"title":"Pravastatin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pravastatin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6826?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pravastatin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pravastatin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=pravastatin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pravastatin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212522\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Pravachol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50644106\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Pravachol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212570\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antilipemic Agent, HMG-CoA Reductase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212527\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Doses should be individualized according to the baseline LDL-cholesterol levels, the recommended goal of therapy, and patient response; adjustments should be made at intervals of 4 weeks or more; doses may need adjusted based on concomitant medications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hyperlipidemias, primary prevention of coronary events, secondary prevention of cardiovascular events (also see ACC/AHA Blood Cholesterol Guideline recommendations):</b> Oral: Initial: 40 mg once daily; titrate dosage to response (maximum dose: 80 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Prevention of cardiovascular disease/reduce the risk of ASCVD: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>ACC/AHA Blood Cholesterol Guideline recommendations (ACC/AHA [Stone 2013]):</b> Adults &ge;21 years:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Primary prevention:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>LDL-C &ge;190 mg/dL:</i> High intensity therapy necessary; use alternate statin therapy (eg, atorvastatin or rosuvastatin)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Type 1 or 2 diabetes and age 40 to 75 years:</i> Moderate intensity therapy: 40 to 80 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Type 1 or 2 diabetes, age 40 to 75 years, and an estimated 10-year ASCVD risk &ge;7.5%:</i> High intensity therapy necessary; use alternate statin therapy (eg, atorvastatin or rosuvastatin)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Age 40 to 75 years and an estimated 10-year ASCVD risk &ge;7.5%:</i> Moderate to high intensity therapy: 40 to 80 mg once daily or consider using high intensity statin therapy (eg, atorvastatin or rosuvastatin)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Secondary prevention:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patient has clinical ASCVD (eg, coronary heart disease, stroke/TIA, or peripheral arterial disease presumed to be of atherosclerotic origin) or is post-CABG (AHA [Kulik 2015]) <b>and</b>:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Age &le;75 years:</i> High intensity therapy necessary; use alternate statin therapy (eg, atorvastatin or rosuvastatin)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Age &gt;75 years or not a candidate for high intensity therapy:</i> Moderate intensity therapy: 40 to 80 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>NLA Dyslipidemia Guideline recommendations (NLA [Jacobson 2015]): </b>Adults &ge;20 years:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary or secondary prevention: Note: </b>Treatment initiation using either moderate- or high-intensity statin therapy is recommended in qualifying patients based on ASCVD risk assessment criteria <b>and</b> baseline non-HDL-C and LDL-C values. Dosage should be individualized based on patient characteristics, tolerance to therapy, and with consideration for non-HDL-C and LDL-C treatment goals.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate-intensity therapy (30% to 50% reduction of LDL-C generally): 40 to 80 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">High-intensity therapy (&ge;50% reduction of LDL-C generally): Use alternate statin therapy (eg, atorvastatin or rosuvastatin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment for pravastatin with concomitant medications:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Clarithromycin:</i>  Maximum pravastatin dose: 40 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cyclosporine:</i> Initial pravastatin dose: 10 mg once daily, titrate with caution (maximum dose: 20 mg/day)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212550\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=pravastatin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pravastatin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Heterozygous familial hypercholesterolemia (HeFH):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents 8 to 13 years: 20 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents 14 to 18 years: 40 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage adjustment for pravastatin with concomitant medications (clarithromycin, cyclosporine):</i></b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Note:</b> Doses should be individualized according to the baseline LDL-cholesterol levels, the recommended goal of therapy, and patient response; adjustments should be made at intervals of 4 weeks or more; doses may need adjusted based on concomitant medications.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212528\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212529\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution.</p>\n    <p style=\"text-indent:0em;\">Severe impairment: Initial: 10 mg once daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212530\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Active hepatic disease or unexplained persistent elevations of serum transaminases: Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22888161\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Severe muscle symptoms or fatigue:</b> Promptly discontinue use; evaluate CPK, creatinine, and urinalysis for myoglobinuria (Stone 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Mild to moderate muscle symptoms:</b> Discontinue use until symptoms can be evaluated; evaluate patient for conditions that may increase the risk for muscle symptoms (eg, hypothyroidism, reduced renal or hepatic function, rheumatologic disorders such as polymyalgia rheumatica, steroid myopathy, vitamin D deficiency, primary muscle diseases).  Upon resolution, resume the original or lower dose of pravastatin. If muscle symptoms recur, discontinue pravastatin use. After muscle symptom resolution, may then use a low dose of a different statin; gradually increase if tolerated. In the absence of continued statin use, if muscle symptoms or elevated CPK continues after 2 months, consider other causes of muscle symptoms. If determined to be due to another condition aside from statin use, may resume statin therapy at the original dose (Stone 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212496\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pravachol: 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pravachol: 40 mg [contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pravachol: 80 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 20 mg, 40 mg, 80 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212481\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212500\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212499\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperlipidemia</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dysbetalipoproteinemia:</b> Treatment of primary dysbetalipoproteinemia (Fredrickson type III) in patients who do not respond adequately to diet.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heterozygous familial hypercholesterolemia:</b> Adjunct to diet in children &ge;8 years and adolescents with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: LDL-C &ge;190 mg/dL or LDL &ge;160 mg/dL with positive family history of premature cardiovascular disease (CVD), or with 2 or more other CVD risk factors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypercholesterolemia and mixed dyslipidemia:</b> Adjunct to diet to reduce elevated total cholesterol, LDL-C, apo B, and triglyceride (TG) levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Has not been studied in conditions where the major lipid abnormality is elevation of chylomicrons (Fredrickson types I and V).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Prevention of cardiovascular disease</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Primary prevention of cardiovascular disease:</b> To reduce the risk of myocardial infarction, revascularization procedures and cardiovascular mortality in hypercholesterolemic patients without established coronary heart disease (CHD).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Secondary prevention of cardiovascular disease:</b> To slow the progression of coronary atherosclerosis; to reduce the risk of myocardial infarction, revascularization procedures, and total mortality; and to reduce the risk of stroke and transient ischemic attacks (TIA) in patients with established CHD.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Guideline recommendations: </i></b>Primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) to reduce the risk of ASCVD in select adult patients (ACC/AHA [Stone 2013]; ADA 2018a; NLA [Jacobson 2015]). Refer to respective guideline for specific recommendations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50324304\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Cardiac risk reduction for noncardiac surgery (perioperative therapy); Noncardioembolic stroke/Transient ischemic attack (secondary prevention)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212578\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pravachol may be confused with atorvaSTATin, Prevacid, Prinivil, propranolol</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pravastatin may be confused with nystatin, pitavastatin, prasugrel</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212488\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As reported in short-term trials; safety and tolerability with long-term use were similar to placebo.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (2% to 6%), fatigue (4%), dizziness (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&le;7%), vomiting (&le;7%), diarrhea (6%), heartburn (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Cystitis (interstitial; Huang 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum transaminases (&gt;3x normal on 2 occasions: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Alopecia, amnesia (reversible), anaphylaxis, angioedema, cataract, change in libido, cholestatic jaundice, cognitive dysfunction (reversible), confusion (reversible), cranial nerve dysfunction, decreased appetite, dermatitis, dermatomyositis, dysgeusia, edema, erythema multiforme, fever, flushing, fulminant hepatic necrosis, gynecomastia, hemolytic anemia, hepatic cirrhosis, hepatic neoplasm, hepatitis, hypersensitivity reaction, increased erythrocyte sedimentation rate, insomnia, lupus-like syndrome, memory impairment (reversible), myasthenia, myopathy, neuropathy, pancreatitis, paresthesia, peripheral nerve palsy, polymyalgia rheumatica, positive ANA titer, pruritus, purpura, rhabdomyolysis, sexual disorder, Stevens-Johnson syndrome, tremor, urticaria, vasculitis, vertigo, xeroderma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212503\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to pravastatin or any component of the formulation; active liver disease; unexplained persistent elevations of serum transaminases; pregnancy; breast-feeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212485\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes mellitus: Increases in HbA<sub>1c</sub> and fasting blood glucose have been reported with HMG-CoA reductase inhibitors; however, the benefits of statin therapy far outweigh the risk of dysglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Endocrine effects: Reduced cholesterol synthesis as a result of therapy could theoretically lead to reduced adrenal or gonadal steroid hormone production; clinical trial data is inconsistent in regards to the effect on basal steroid hormone levels. Patients with signs/symptoms of endocrine dysfunction should be evaluated as clinically indicated; use caution with concomitant medications (eg, spironolactone, cimetidine, ketoconazole) that may reduce steroid hormone levels/activity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Postmarketing reports of fatal and nonfatal hepatic failure are rare. If serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, interrupt therapy. If an alternate etiology is not identified, do not restart pravastatin. Liver enzyme tests should be obtained at baseline and as clinically indicated; routine periodic monitoring of liver enzymes is not necessary. Ethanol may enhance the potential of adverse hepatic effects; instruct patients to avoid excessive ethanol consumption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immune-mediated necrotizing myopathy (IMNM): IMNM, an autoimmune-mediated myopathy, has been reported (rarely) with HMG-CoA reductase inhibitor therapy. IMNM presents as proximal muscle weakness with elevated CPK levels, which persists despite discontinuation of HMG-CoA reductase inhibitor therapy; additionally, muscle biopsy may show necrotizing myopathy with limited inflammation. Immunosuppressive therapy (eg, corticosteroids, azathioprine) may be used for treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myopathy/rhabdomyolysis: Rhabdomyolysis with acute renal failure secondary to myoglobinuria and/or myopathy have been reported; patients should be monitored closely. This risk is dose-related and is increased with concurrent use of erythromycin, cyclosporine, fibric acid derivatives (eg, gemfibrozil), or niacin (doses &ge;1 g/day). Temporarily withhold therapy in patients experiencing conditions predisposing to the development of renal failure secondary to rhabdomyolysis (eg, sepsis, hypotension, major surgery, trauma, uncontrolled epilepsy; severe metabolic, endocrine, or electrolyte disorders). Discontinue therapy in any patient in which CPK levels are markedly elevated (&gt;10 times ULN) or if myopathy is suspected/diagnosed. Use caution in patients with inadequately treated hypothyroidism, and those taking other drugs associated with myopathy (eg, colchicine); these patients are predisposed to myopathy. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment and/or ethanol use: Use with caution in patients who consume large amounts of ethanol or have a history of liver disease. Use is contraindicated in patients with active liver disease or unexplained transaminase elevations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; these patients are predisposed to myopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special Populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in patients with advanced age, these patients are predisposed to myopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: The manufacturer recommends temporary discontinuation for elective major surgery, acute medical or surgical conditions, or in any patient experiencing an acute or serious condition predisposing to renal failure (eg, sepsis, hypotension, trauma, uncontrolled seizures). Based on current research and clinical guidelines, HMG-CoA reductase inhibitors should be continued in the perioperative period for noncardiac and cardiac surgery (ACC/AHA [Fleisher 2014]; ACC/AHA [Hillis 2011]). Perioperative discontinuation of statin therapy is associated with an increased risk of cardiac morbidity and mortality.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Has not been studied in homozygous familial hypercholesterolemia (statins may be less effective due to lack of functional LDL receptors).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212564\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor), OATP1B1/SLCO1B1, P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212490\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9804&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May increase the serum concentration of Pravastatin. Management: Limit the pravastatin dose to a maximum of 40 mg per day when used with antihepaciviral combination products and monitor patients for evidence of pravastatin toxicities (eg, myopathy).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Pravastatin. Management: Administer pravastatin at least 1 hour before or 4 hours after administration of bile-acid resins (eg, cholestyramine, colestipol, colesevelam) to minimize the risk for any significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Pravastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Management: Avoid the use of HMG-CoA reductase inhibitors and ciprofibrate if possible. If concomitant therapy is considered, benefits should be carefully weighed against the risks, and patients should be monitored closely for signs/symptoms of muscle toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clarithromycin: May increase the serum concentration of Pravastatin. Management: Limit pravastatin to a maximum of 40 mg/day (for adults) when used in combination with clarithromycin.  If this combination is used, monitor patients more closely for evidence of pravastatin toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May increase the serum concentration of Pravastatin. Pravastatin may increase the serum concentration of CycloSPORINE (Systemic). Management: Limit pravastatin to 20 mg/day in patients who are also receiving cyclosporine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclatasvir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DAPTOmycin: HMG-CoA Reductase Inhibitors (Statins) may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of Pravastatin. This effect has been demonstrated with darunavir/ritonavir and may occur with darunavir/cobicistat. The individual contributions of darunavir, ritonavir, and cobicistat are unknown.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Pravastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erythromycin (Systemic): May increase the serum concentration of Pravastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fenofibrate and Derivatives: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use whenever possible. Use is listed as contraindicated in product characteristic summaries in several countries, although UK labeling suggests that use could be considered under exceptional circumstances and with close supervision.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of Pravastatin. Gemfibrozil may increase the serum concentration of Pravastatin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glecaprevir and Pibrentasvir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Use the lowest statin dose possible if combined with glecaprevir/pibrentasvir and monitor for increased statin effects/toxicities. Avoid concomitant use with atorva-, simva-, or lovastatin. Limit rosuvastatin to 10 mg daily and reduce pravastatin dose 50%<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: May increase the serum concentration of Pravastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: HMG-CoA Reductase Inhibitors (Statins) may decrease the serum concentration of Lanthanum.  Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Letermovir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: May decrease the serum concentration of Pravastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Niacinamide: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PARoxetine: Pravastatin may enhance the adverse/toxic effect of PARoxetine. Specifically, blood glucose elevations may occur with the combination. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: HMG-CoA Reductase Inhibitors (Statins) may enhance the hepatotoxic effect of PAZOPanib. Specifically, the risk for increased serum transaminase concentrations may be increased.  Management: Simvastatin is specifically implicated in the interaction. There is a lack of data regarding risk with other statins, but caution appears warranted with any statins. Atorvastatin should be avoided due to P-gp inhibition.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltegravir: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Repaglinide: HMG-CoA Reductase Inhibitors (Statins) may increase the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rupatadine: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Specifically, the risk for increased CPK and/or other muscle toxicities may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: May decrease the serum concentration of Pravastatin. This effect has only been demonstrated with saquinavir/ritonavir. The individual contributions of saquinavir and ritonavir are unknown.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of Pravastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Pravastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telithromycin: May increase the serum concentration of Pravastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trabectedin: HMG-CoA Reductase Inhibitors (Statins) may enhance the myopathic (rhabdomyolysis) effect of Trabectedin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): HMG-CoA Reductase Inhibitors (Statins) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voxilaprevir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Use the lowest statin dose possible if combined with voxilaprevir and monitor patients for increased statin effects/toxicities. Avoid concomitant use of voxilaprevir with rosuvastatin or pitavastatin, and limit pravastatin doses to 40 mg daily.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212492\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212506\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Use of pravastatin is contraindicated in pregnancy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Adverse events were observed in some animal reproduction studies. Pravastatin was found to cross the placenta in an ex vivo study using term human placentas (Nanovskaya 2013). There are reports of congenital anomalies following maternal use of HMG-CoA reductase inhibitors in pregnancy; however, maternal disease, differences in specific agents used, and the low rates of exposure limit the interpretation of the available data (Godfrey 2012; Lecarpentier 2012). Cholesterol biosynthesis may be important in fetal development; serum cholesterol and triglycerides increase normally during pregnancy. The discontinuation of lipid lowering medications temporarily during pregnancy is not expected to have significant impact on the long term outcomes of primary hypercholesterolemia treatment.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Because they are potentially teratogenic, the ADA Diabetes guidelines recommends avoiding use of HMG-CoA reductase inhibitors in sexually active women of childbearing age who are not using reliable contraception (ADA 2018b). If treatment of dyslipidemias is needed in pregnant women or in women of reproductive age, other agents are preferred (Berglund 2012; Stone 2013). The manufacturer recommends administration to women of childbearing potential only when conception is highly unlikely and patients have been informed of potential hazards.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16609564\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Use of pravastatin in breast-feeding women is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">A small amount of pravastatin is excreted into breast milk. Data is available from eight lactating females administered pravastatin 20 mg twice daily for 2.5 days. After the fifth dose, maximum maternal serum concentrations were ~40 ng/mL (pravastatin) and ~26 ng/mL (metabolite) and maximum milk concentrations were ~3.9 ng/mL (pravastatin) and ~2.1 ng/mL (metabolite). Maximum milk concentrations were detected ~3 hours after the dose (Pan 1988).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212507\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Before initiation of therapy, patients should be placed on a standard cholesterol-lowering diet for 6 weeks and the diet should be continued during drug therapy.  </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Red yeast rice contains variable amounts of several compounds that are structurally similar to HMG-CoA reductase inhibitors, primarily monacolin K (or mevinolin) which is structurally identical to lovastatin; concurrent use of red yeast rice with HMG-CoA reductase inhibitors may increase the incidence of adverse and toxic effects (Lapi 2008; Smith 2003). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212494\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>2013 ACC/AHA Blood Cholesterol Guideline recommendations (Stone 2013):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <b>Lipid panel (total cholesterol, HDL, LDL, triglycerides):</b> Baseline lipid panel; fasting lipid profile within 4-12 weeks after initiation or dose adjustment and every 3-12 months (as clinically indicated) thereafter. If 2 consecutive LDL levels are &lt;40 mg/dL, consider decreasing the dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatic transaminase levels:</b> Baseline measurement of hepatic transaminase levels (ie, ALT); measure hepatic function if symptoms suggest hepatotoxicity (eg, unusual fatigue or weakness, loss of appetite, abdominal pain, dark-colored urine or yellowing of skin or sclera) during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CPK:</b> CPK should not be routinely measured. Baseline CPK measurement is reasonable for some individuals (eg, family history of statin intolerance or muscle disease, clinical presentation, concomitant drug therapy that may increase risk of myopathy). May measure CPK in any patient with symptoms suggestive of myopathy (pain, tenderness, stiffness, cramping, weakness, or generalized fatigue).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Evaluate for new-onset diabetes mellitus during therapy; if diabetes develops, continue statin therapy and encourage adherence to a heart-healthy diet, physical activity, a healthy body weight, and tobacco cessation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If patient develops a confusional state or memory impairment, may evaluate patient for nonstatin causes (eg, exposure to other drugs), systemic and neuropsychiatric causes, and the possibility of adverse effects associated with statin therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Manufacturer's labeling:</i></b>  Liver enzyme tests at baseline and repeated when clinically indicated. <b>Upon initiation or titration, lipid panel should be analyzed at intervals of 4 weeks or more. </b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49042883\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;\">\n      <b>Treatment goals: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>American Association of Clinical Endocrinologists/American College of Endocrinology recommendations (AACE/ACE [Jellinger 2017]):</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Low risk (no risk factors):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C: &lt;160 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C: &lt;130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ApoB: No recommendation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Moderate (&le;2 risk factors; 10-year risk &lt;10%) or high risk (diabetes; CKD stage 3 to 4; &ge;2 risk factors and 10-year risk 10% to 20%):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C: &lt;130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C: &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apo B: &lt;90 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Very high risk (ACS; carotid/peripheral artery disease; diabetes or CKD stage 3 to 4 with &ge;1 risk factors; HeFH; 10-year risk &gt;20%):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C: &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C: &lt;70 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apo B: &lt;80 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Extreme risk (progressive atherosclerotic CVD after achieving LDL</i>\n      <i>&#8208;C &lt;70 mg/dL; CVD and diabetes, CKD stage 3 to 4, or HeFH; history of premature atherosclerotic CVD (&lt;55 years [males]; &lt;65 years [females]):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C: &lt;80 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C: &lt;55 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apo B: &lt;70 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>National Lipid Association Dyslipidemia recommendations </b>\n      <b>(NLA [Jacobson 2015])</b>\n      <b>: </b>Adults &ge;20 years:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Low-, moderate-, or high-risk patient categories: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C &lt;130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apo B &lt;90 mg/dL (Apo B is a secondary, optional target of treatment for patients that have achieved treatment goals for non-HDL-C and LDL-C)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note: </b>For patients with diabetes plus 1 major ASCVD risk factor (ie, <i>high risk </i>category), treating to a non&ndash;HDL-C goal of &lt;100 mg/dL (LDL-C of &lt;70 mg/dL) may be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Very high-risk patient category:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HDL-C &lt;100 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LDL-C &lt;70 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apo B &lt;80 mg/dL (Apo B is a secondary, optional target of treatment for patients that have achieved treatment goals for non-HDL-C and LDL-C)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212484\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Pravastatin is a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which is the rate-limiting enzyme involved in <i>de novo</i> cholesterol synthesis. In addition to the ability of HMG-CoA reductase inhibitors to decrease levels of high-sensitivity C-reactive protein (hsCRP), they also possess pleiotropic properties including improved endothelial function, reduced inflammation at the site of the coronary plaque, inhibition of platelet aggregation, and anticoagulant effects (de Denus 2002; Ray 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212502\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Several days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LDL-reduction: 40 mg/day: 34% (for each doubling of this dose, LDL-C is lowered by ~6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapidly absorbed; average absorption 34%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 0.46 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~50%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic multiple metabolites; primary metabolite is 3 alpha-hydroxy-iso-pravastatin (2.5% to 10% activity of parent drug); extensive first-pass metabolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 17%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents (4.9 to 15.6 years): 1.6 hours; range: 0.85 to 4.2 hours (Hedman 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 77 hours (including all metabolites); Pravastatin: ~2 to 3 hours (Pan 1990); 3 alpha-hydroxy-iso-pravastatin: ~1.5 hours (Gustavson 2005) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 1 to 1.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (70%); urine (~20%, 8% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212505\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Pravachol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (90): $416.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (90): $610.99</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (90): $610.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Pravastatin Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (90): $289.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (90): $294.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (90): $431.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (90): $431.50</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212508\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Astin (MX);</li>\n      <li>Brakhor (MX);</li>\n      <li>Bristacol (ES);</li>\n      <li>Brufincol (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Cholespar (ID);</li>\n      <li>Cholstat (AU);</li>\n      <li>Col-Alphar (MX);</li>\n      <li>Colpradin (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Elisor (FR);</li>\n      <li>Emipastin (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Genoestatina (MX);</li>\n      <li>Kenstatin (MX);</li>\n      <li>Koloskol (ID);</li>\n      <li>Lipemol (ES);</li>\n      <li>Lipista (VN);</li>\n      <li>Liplat (ES);</li>\n      <li>Lipostat (AE, AU, BG, BH, CZ, EE, EG, GB, HU, IE, JO, KW, LB, PL, QA, SA);</li>\n      <li>Liprevil (DE);</li>\n      <li>Loretsin (MX);</li>\n      <li>Lowchol (JO);</li>\n      <li>Mechol (TW);</li>\n      <li>Mevalotin (CN, DE, ID, JP, KR);</li>\n      <li>Mevalotin Protect (TH);</li>\n      <li>Novales (ID);</li>\n      <li>Novina (MX);</li>\n      <li>Pitaduce (KR);</li>\n      <li>Prastan (KR);</li>\n      <li>Pratin (MY, TW);</li>\n      <li>Prava (ZA);</li>\n      <li>Pravachol (AT, AU, BB, BM, BS, BZ, DK, FI, GR, GY, HK, JM, NO, NZ, PE, PK, SE, SR, TR, TT, VE);</li>\n      <li>Pravacol (AR, BR, CL, EC, MX, PE, PT);</li>\n      <li>Pravalip (IL);</li>\n      <li>Pravamel (IE);</li>\n      <li>Pravapres (UA);</li>\n      <li>Pravaselect (IT);</li>\n      <li>Pravasin (DE, LU);</li>\n      <li>Pravasine (BE);</li>\n      <li>Pravat (IE);</li>\n      <li>Pravator (IN, RO);</li>\n      <li>Pravaz (PH);</li>\n      <li>Pravitin (IE);</li>\n      <li>Pravyl (CO);</li>\n      <li>Pu Hui Zhi (CN);</li>\n      <li>Sanaprav (AT, IT);</li>\n      <li>Selectin (IT);</li>\n      <li>Selektine (NL);</li>\n      <li>Selipran (AT, CH);</li>\n      <li>Tissulest (MX);</li>\n      <li>Vasten (FR);</li>\n      <li>Vastoran (AU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018a;41(suppl 1): S86-S104. doi: 10.2337/dc18-S009.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/29222380/pubmed\" target=\"_blank\" id=\"29222380\">29222380</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222384\"></a>American Diabetes Association (ADA). 13. Management of diabetes in pregnancy: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018b;41(suppl 1):S137-S143. doi: 10.2337/dc18-S013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/29222384/pubmed\" target=\"_blank\" id=\"29222384\">29222384</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berglund L, Brunzell JD, Goldberg AC, et al, &ldquo;Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline,&rdquo; <i>J Clin Endocrinol Metab</i>, 2012, 97(9):2969-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/22962670/pubmed\" target=\"_blank\" id=\"22962670\">22962670</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, &quot;Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,&quot; <i>Can J Diabetes</i>, 2013, 35(Suppl 1):1-212.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Castro C and Gourley M, &quot;Diagnosis and Treatment of Inflammatory Myopathy: Issues and Management,&quot; <i>Ther Adv Musculoskelet Dis</i>, 2012, 4(2):111-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/22870499/pubmed\" target=\"_blank\" id=\"22870499\">22870499</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Denus S and Spinler SA, &ldquo;Early Statin Therapy for Acute Coronary Syndromes,&rdquo; <i>Ann Pharmacother</i>, 2002, 36(11):1749-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/12398573/pubmed\" target=\"_blank\" id=\"12398573\">12398573</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis J, Tardif JC, Cernacek P, et al, &ldquo;Cholesterol Reduction Rapidly Improves Endothelial Function After Acute Coronary Syndromes. The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) Trial,&rdquo; <i>Circulation</i>, 1999, 99(25):3227-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/10385495/pubmed\" target=\"_blank\" id=\"10385495\">10385495</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fernandez AB, Karas RH, Alsheikh-Ali AA, et al, &ldquo;Statins and Interstitial Lung Disease: A Systematic Review of the Literature and of Food and Drug Administration Adverse Event Reports,&rdquo; <i>Chest</i>, 2008, 134(4):824-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/18689579/pubmed\" target=\"_blank\" id=\"18689579\">18689579</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo; <i>Circulation</i>, 2012, 126(25):3097-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/23166211/pubmed\" target=\"_blank\" id=\"23166211\">23166211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(24):e278-e333.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/25085961/pubmed\" target=\"_blank\" id=\"25085961\">25085961</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fonarow GC, French WJ, Parsons LS, et al, &ldquo;Use of Lipid-Lowering Medications at Discharge in Patients With Acute Myocardial Infarction: Data From the National Registry of Myocardial Infarction 3,&rdquo; <i>Circulation</i>, 2001, 103(1):38-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/11136683/pubmed\" target=\"_blank\" id=\"11136683\">11136683</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Godfrey LM, Erramouspe J, and Cleveland KW, &quot;Teratogenic Risk of Statins in Pregnancy,&quot; <i>Ann Pharmacother</i>, 2012, 46(10):1419-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/23032657/pubmed\" target=\"_blank\" id=\"23032657\">23032657</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gustavson LE, Schweitzer SM, Koehne-Voss S, et al, &quot;The Effects of Multiple Doses of Fenofibrate on the Pharmacokinetics of Pravastatin and Its 3-Alpha-Hydroxy Isomeric Metabolite,&quot; <i>J Clin Pharmacol</i>, 2005, 45(8):947-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/16027406/pubmed\" target=\"_blank\" id=\"16027406\">16027406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hedman M, Neuvonen PJ, Neuvonen M, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Pravastatin in Children With Familial Hypercholesterolemia,&rdquo; <i>Clin Pharmacol Ther</i>, 2003, 74(2):178-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/12891228/pubmed\" target=\"_blank\" id=\"12891228\">12891228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heeschen C, Hamm CW, Laufs U, et al, &ldquo;Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes,&rdquo; <i>Circulation</i>, 2002, 105(12):1446-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/11914253/pubmed\" target=\"_blank\" id=\"11914253\">11914253</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Huang CY, Chung SD, Kao LT, Lin HC, Wang LH. Statin use is associated with bladder pain syndrome/interstitial cystitis: a population-based case-control study. <i>Urol Int</i>. 2015;95(2):227-232.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/26184102/pubmed\" target=\"_blank\" id=\"26184102\">26184102</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. <i>J Clin Lipidol</i>. 2015;9(2):129-169. doi: 10.1016/j.jacl.2015.02.003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/25911072/pubmed\" target=\"_blank\" id=\"25911072\">25911072</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. <i>Endocr Pract</i>. 2017;23(suppl 2):1-87. doi: 10.4158/EP171764.APPGL.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/28437620/pubmed\" target=\"_blank\" id=\"28437620\">28437620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24788967\"></a>Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in <i>Stroke</i>. 2015;46(2):e54]. <i>Stroke</i>. 2014;45(7):2160-2236. doi: 10.1161/STR.0000000000000024.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/24788967/pubmed\" target=\"_blank\" id=\"24788967\">24788967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koren MJ, Smith DG, Hunninghake DB, et al, &ldquo;The Cost of Reaching National Cholesterol Education Program (NCEP) Goals in Hypercholesterolaemic Patients. A Comparison of Atorvastatin, Simvastatin, Lovastatin and Fluvastatin,&rdquo; <i>Pharmacoeconomics</i>, 1998, 14(1):59-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/10182195/pubmed\" target=\"_blank\" id=\"10182195\">10182195</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kulik A, Ruel M, Jneid H, et al; American Heart Association Council on Cardiovascular Surgery and Anesthesia. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;131 (10):927-964.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/25679302/pubmed\" target=\"_blank\" id=\"25679302\">25679302</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lapi F, Gallo E, Bernasconi S, et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. <i>Br J Clin Pharmacol</i>. 2008;66(4):572-574.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/18637891/pubmed\" target=\"_blank\" id=\"18637891\">18637891</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LaRosa JC, Grundy SM, Waters DD, et al, &ldquo;Intensive Lipid Lowering With Atorvastatin in Patients With Stable Coronary Disease,&rdquo; <i>N Engl J Med</i>, 2005, 352(14):1425-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/15755765/pubmed\" target=\"_blank\" id=\"15755765\">15755765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lecarpentier E, Morel O, Fournier T, et al, &quot;Statins and Pregnancy: Between Supposed Risks and Theoretical Benefits,&quot; <i>Drugs</i>, 2012, 72(6):773-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/22480340/pubmed\" target=\"_blank\" id=\"22480340\">22480340</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LeManach Y, Godet G, Coriat P, et al, &ldquo;The Impact of Postoperative Discontinuation or Continuation of Chronic Statin Therapy on Cardiac Outcome After Major Vascular Surgery,&rdquo; <i>Anesth Analg</i>, 2007, 104(6):1326-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/17513620/pubmed\" target=\"_blank\" id=\"17513620\">17513620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lewis SJ, Moye LA, Sacks FM, et al, &ldquo;Effect of Pravastatin on Cardiovascular Events in Older Patients With Myocardial Infarction and Cholesterol Levels in the Average Range. Results of the Cholesterol and Recurrent Events (CARE) Trial,&rdquo; <i>Ann Intern Med</i>, 1998, 129(9):681-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/9841599/pubmed\" target=\"_blank\" id=\"9841599\">9841599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McPherson R, Frohlich J, Fodor G, et al, &ldquo;Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease,&rdquo; [published correction appears in <i>Can J Cardiol</i>. 2006, 22(12):1077]. <i>Can J Cardiol</i>. 2006;22(11):913-927.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/16971976/pubmed\" target=\"_blank\" id=\"16971976\">16971976</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;MRC/BHF Heart Protection Study of Cholesterol Lowering With Simvastatin in 20,536 High-Risk Individuals: A Randomised Placebo-Controlled Trial. Heart Protection Study Collaborative Group,&rdquo; <i>Lancet</i>, 2002, 360(9326):7-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/12114036/pubmed\" target=\"_blank\" id=\"12114036\">12114036</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nanovskaya TN, Patrikeeva SL, Paul J, et al. Transplacental transfer and distribution of pravastatin. <i>Am J Obstet Gynecol</i>. 2013;209(4):373.e1-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/24070396/pubmed\" target=\"_blank\" id=\"24070396\">24070396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pan H, Fleiss P, Moore L, et al, &quot;Excretion of Pravastatin, an HMG CoA Reductase Inhibitor, in Breast Milk of Lactating Women. American College of Clinical Pharmacology seventeenth annual meeting. October 31-November 3, 1988, Orlando, Florida. Abstracts,&quot; <i>J Clin Pharmacol</i>, 1988, 28(10):942.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/3220964/pubmed\" target=\"_blank\" id=\"3220964\">3220964</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pan HY, DeVault AR, Swites BJ, et al, &quot;Pharmacokinetics and Pharmacodynamics of Pravastatin Alone and With Cholestyramine in Hypercholesterolemia,&quot; <i>Clin Pharmacol Ther</i>, 1990, 48(2):201-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/2116260/pubmed\" target=\"_blank\" id=\"2116260\">2116260</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al, &ldquo;ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins,&rdquo; Stroke, 2002, 33(9):2337-41. Available at http://stroke.ahajournals.org/cgi/content/short/33/9/233712215610</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pearson TA, Mensah GA, Alexander RW, et al, &ldquo;Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association,&rdquo; <i>Circulation</i>, 2003, 107(3):499-511.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/12551878/pubmed\" target=\"_blank\" id=\"12551878\">12551878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips BG, Yim JM, Brown EJ Jr, et al, &ldquo;Pharmacologic Profile of Survivors of Acute Myocardial Infarction at United States Academic Hospitals,&rdquo; <i>Am Heart J</i>, 1996, 131(5):872-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/8615304/pubmed\" target=\"_blank\" id=\"8615304\">8615304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poldermans D, Bax JJ, Kertai MD, et al, &ldquo;Statins Are Associated With a Reduced Incidence of Perioperative Mortality in Patients Undergoing Major Noncardiac Vascular Surgery,&rdquo; <i>Circulation</i>, 2003, 107(14):1848-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/12695283/pubmed\" target=\"_blank\" id=\"12695283\">12695283</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pravachol (pravastatin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Prevention of Cardiovascular Events and Death With Pravastatin in Patients With Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group,&rdquo; <i>N Engl J Med</i>, 1998, 339(19):1349-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/9841303/pubmed\" target=\"_blank\" id=\"9841303\">9841303</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ray KK and Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. <i>J Am Coll Cardiol</i>. 2005;46(8):1425-1433.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/16226165/pubmed\" target=\"_blank\" id=\"16226165\">16226165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ridker PM, Danielson E, Fonseca FAH, et al, &ldquo;Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein,&rdquo; <i>N Engl J Med</i>, 2008, 359(21):2195-207.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/18997196/pubmed\" target=\"_blank\" id=\"18997196\">18997196</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sacks FM, Pfeffer MA, Moye LA, et al, &ldquo;The Effect of Pravastatin on Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels. Cholesterol and Recurrent Events Trial Investigators,&rdquo; <i>N Engl J Med</i>, 1996, 335(14):1001-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/8801446/pubmed\" target=\"_blank\" id=\"8801446\">8801446</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sever PS, Dahlof B, Poulter NR, et al, &ldquo;Prevention of Coronary and Stroke Events With Atorvastatin in Hypertensive Patients Who Have Average or Lower-Than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial,&rdquo; <i>Lancet</i>, 2003, 361(9364):1149-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/12686036/pubmed\" target=\"_blank\" id=\"12686036\">12686036</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shepherd J, Cobbe SM, Ford I, et al, &ldquo;Prevention of Coronary Heart Disease With Pravastatin in Men With Hypercholesterolemia. West of Scotland Coronary Prevention Study Group,&rdquo; <i>N Engl J Med</i>, 1995, 333(20):1301-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/7566020/pubmed\" target=\"_blank\" id=\"7566020\">7566020</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith DJ, Olive KE. Chinese red rice-induced myopathy. <i>South Med J</i>. 2003;96(12):1265-1267.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/14696880/pubmed\" target=\"_blank\" id=\"14696880\">14696880</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stone NJ, Robinson J, Lichtenstein AH, et al, 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online ahead of print November 12, 2013].<i>Circulation</i>. 2013; doi: 10.1161/01.cir.0000437738.63853.7a.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tonelli M, Wanner C; for the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid Management in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 Clinical Practice Guideline [published online ahead of print]. <i>Ann Intern Med</i>. 2013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/24323134/pubmed\" target=\"_blank\" id=\"24323134\">24323134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    White HD, Simes RJ, Anderson NE, et al, &ldquo;Pravastatin Therapy and the Risk of Stroke,&rdquo; <i>N Engl J Med</i>, 2000, 343(5):317-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pravastatin-drug-information/abstract-text/10922421/pubmed\" target=\"_blank\" id=\"10922421\">10922421</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9804 Version 231.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F212522\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50644106\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F212570\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F212527\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F212550\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F212528\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F212529\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F212530\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F22888161\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F212496\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F212481\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F212500\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F212499\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F50324304\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F212578\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F212488\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F212503\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F212485\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F212564\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F212490\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F212492\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F212506\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16609564\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F212507\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F212494\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F49042883\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F212484\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F212502\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F212505\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F212508\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9804|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pravastatin-patient-drug-information\" class=\"drug drug_patient\">Pravastatin: Patient drug information</a></li><li><a href=\"topic.htm?path=pravastatin-pediatric-drug-information\" class=\"drug drug_pediatric\">Pravastatin: Pediatric drug information</a></li></ul></div></div>","javascript":null}